Spain continues to work on coronavirus vaccine with denomination of origin. It has been known for months that it will arrive late with respect to the rest of the antidotes. To counteract this delay, it is intended to develop a novel serum and unique whose results are “spectacular”.
Luis Enjuanes, one of the experts behind this vaccine, explained in the presentation of the Strategic Plan of Donations of the Spanish Union of Insurance Entities that the vaccine that his team is developing “is a promising candidate.”
“The mice vaccinated with 100,000 infective units achieved total immunity and did not allow the replication of the virus at any time”, the scientist has detailed.
In addition, Enjuanes himself pointed out a few months ago that the price of the vaccine from the Higher Council for Scientific Research, the Spanish state agency attached to the Ministry of Science and Innovation, would have an almost symbolic price.
However, that the application of this serum is por vía intranasal may end up being a problem because agencies prefer needle stick inoculation. Thus, it is expected that in the near future it will be investigated whether the CSIC vaccine would have the same success if it were applied intramuscularly.
Despite this possible setback Enjuanes has defended that the vaccine be inoculated through the nose: “This virus enters our body primarily through the respiratory tract, so if you administer the vaccine intranasally, you immunize that area and protection is greater.”
In addition, the Spanish vaccine that Enjuanes is working on only needs a small dose to take effect because within the patient’s body it replicates itself.
The vaccine developed by Enjuanes is not the only one that is being created in Spain since there are currently a dozen of them that are being worked on. However, none have managed to reach the clinical phase.
–
